Key result
PAH and its therapies are linked to decreased sexual frequency in ~92% of women.
Why the study?
Sexual health–related quality of life is poorly understood in women with pulmonary arterial hypertension despite its importance in disease management.
Observational (n=13)
Women with PAH experience significant declines in sexual health-related quality of life, often leading to compensatory behaviors that can compromise adherence to essential therapies like oxygen and parenteral prostanoids.
Sexual health impairment in women with PAH may affect adherence; cross-sectional data leave open whether interventions improve quality of life or outcomes.
Rationale Health-related quality of life in patients with pulmonary arterial hypertension (PAH) has become increasingly important in disease management as numerous treatment options have improved prognosis and time to clinical worsening. Sexual health–related quality of life (SHRQoL) is poorly understood in patients with PAH, but previous work has shown that patients may face unrecognized challenges, especially related to parenteral prostanoid analogue therapies. Objectives Using qualitative methods, to describe challenges and perspectives related to SHRQoL among women with PAH. Methods We conducted 13 semistructured in-depth interviews at the Pulmonary Hypertension Association’s International Pulmonary Hypertension Conference and Scientific Sessions among female attendees with World Symposium on Pulmonary Hypertension group 1 PAH. A coding structure using both deductive and inductive coding was developed to organize and analyze data using applied thematic analysis. Salient themes were identified and are presented here using summary and illustrative quotations. Results Ninety-two percent (12 of 13) of participants reported declines in the frequency of sex after diagnosis of PAH. A significant portion (62% [8 of 13]) experienced fear of having sexual intercourse because of cardiopulmonary symptoms. All participants (100% [13 of 13]) reported compensatory behaviors/strategies during and around sexual intercourse; some participants on subcutaneous prostanoids also reported timing intercourse to coincide with infusion site changes and, as a result, interrupted treatment during this time. Participants reported changing positions during sex to reduce breathlessness, and some reported removing oxygen to avoid interrupting intimacy. Most participants endorsed negative body image related to their medications, external oxygen supplementation, and/or body weight fluctuations (54% [7 of 13]). Many participants revealed that they had never discussed sexual practices with healthcare professionals and desired increased communication and discussion with their providers. Conclusions Women with PAH face significant burdens and challenges regarding SHRQoL. PAH therapies directly affect SHRQoL. Further targeted qualitative and quantitative studies are needed to better characterize and improve SHRQoL in patients with PAH.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an observational in Pulmonary Arterial Hypertension (n=13). Pulmonary arterial hypertension was evaluated on Challenges and perspectives related to sexual health-related quality of life. Pulmonary arterial hypertension and its therapies significantly impacted sexual health, with 92% of women reporting decreased sexual frequency and 100% using compensatory behaviors during intercourse.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: